Simvastatin repurposing towards endometriosis management: The use of self -nanoemulsifying drug delivery system

---

Authors

Payel Chakraborty¹ , Tamilvanan Shunmugaperumal¹

1. NIPER, Guwahati

Conference / event

International Symposium on Recent Trends and Future Opportunities in Pharmaceuticals, November 2022 (Virtual)

Poster summary

Simvastatin is having pleiotropic effects. This current study aimed to manage endometriosis by repurposing simvastatin into self-nanoemulsifying drug delivery system. RP-HPLC method was developed and validated for simvastatin followed by solubility study in oils, surfactants, and co-surfactants. The vehicles showing the highest solubility for simvastatin were used for creating pseudo-ternary phase diagram to obtain the concentration range for a stable emulsion. Formulation optimization was done systemically by formulation by design approach (FbD) which includes the Ishikawa fishbone diagram as one of the initial risk assessment parameters.

Keywords

Self-nanoemulsifying drug delivery system, Simvastatin, Endometriosis, Ishikawa fishbone diagram

Research areas

Pharmacy and Pharmacology

References

1. Jing YS, Ma YF, Pan FB, Li MS, Zheng YG, Wu LF, Zhang DS. An insight into antihyperlipidemic effects of polysaccharides from natural resources. Molecules. 2022 Mar 15;27(6):1903.
2. Sokalska A, Cress A, Bruner-Tran KL, Osteen KG, Taylor HS, Ortega I, Duleba AJ. Simvastatin decreases invasiveness of human endometrial stromal cells. Biology of reproduction. 2012 Jul 1;87(1):2-1.
3. Wong JC, Fiscus RR. Resveratrol at anti-angiogenesis/anticancer concentrations suppresses protein kinase G signaling and decreases IAPs expression in HUVECs. Anticancer research. 2015 Jan 1;35(1):273-81.

Funding

No data provided

Supplemental files

1. Supporting Information about Self Nanoemulsifying Drug Delivery Systems   Download
2. Self Nanoemulsifying Drug Delivery Systems preparation   Download

Additional information

Competing interests

No competing interests were disclosed.

Data availability statement

The datasets generated during and / or analyzed during the current study are available from the corresponding author on reasonable request.

Creative Commons license

Copyright © 2023 Chakraborty et al. This is an open access work distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.